Orchestra BioMed Holdings Inc OBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $3.72
- Day Range
- $3.63–3.74
- 52-Week Range
- $2.20–5.42
- Bid/Ask
- $3.55 / $4.20
- Shares Outstanding
- 59.88M
- Market Cap
- $220.36M
- Volume/Avg
- 200,318 / 328,629
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.12
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 86
- Website
- https://www.orchestrabiomed.com
Valuation
|
Metric
|
OBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.29 |
Price/Sales | 6.12 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OBIO
|
|---|---|
Quick Ratio | 6.90 |
Current Ratio | 7.03 |
Interest Coverage | −24.59 |
Quick Ratio
OBIO
Profitability
|
Metric
|
OBIO
|
|---|---|
Return on Assets (Normalized) | −53.31% |
Return on Equity (Normalized) | −144.60% |
Return on Invested Capital (Normalized) | −90.73% |
Return on Assets
OBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Jg^%!bR | LOCK|S%Hx | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|v#x$R> | LOCK|s!zPM | $70B | |||
| argenx SE ADR
ARGX
| LOCK|!^NqGJ! | LOCK|R#$ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|d>zQ!^B | LOCK|?M#D | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%Ld!Nk | LOCK|rJ | $37B | |||
| Moderna Inc
MRNA
| LOCK|<x#@fyk | LOCK|$r | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|gsSs>xj | LOCK|?G@? | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|R#x<Ny | LOCK|<s | $23B | |||
| Incyte Corp
INCY
| LOCK|h&!J>W | LOCK|<q | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|v&SqlkF | LOCK|@f | $16B |
United States